Key result
Egr-1 AS-ODN attenuates myocardial injury and inflammation from ischemia-reperfusion in preclinical models.
Why the study?
Does Egr-1 AS-ODN reduce myocardial injury and inflammation in rat models of ischemia-reperfusion and hypoxia-reoxygenation?
Population
Sprague-Dawley rat myocardial ischemia-reperfusion model and cultured cardiomyocyte hypoxia-reoxygenation…
Design
Preclinical
Authors
Loading...
Hypothesis-generating for Egr-1 targeting in myocardial ischemia-reperfusion; clinical translation untested and should not yet change practice.
Does Egr-1 AS-ODN reduce myocardial injury and inflammation in rat models of ischemia-reperfusion and hypoxia-reoxygenation?
Egr-1 AS-ODN protects against myocardial ischemia-reperfusion injury in preclinical models, suggesting Egr-1 as a potential therapeutic target.
Zhang et al. (2008) studied Myocardial ischemia-reperfusion injury. Egr-1 antisense oligodeoxyribonucleotide (AS-ODN) was evaluated on Hemodynamic parameters, myeloperoxidase, cardiac troponin I, tumor necrosis factor-alpha, morphology, spontaneous beat and cell viability. Egr-1 antisense oligodeoxyribonucleotide significantly attenuated injury and inflammation of myocardial tissues caused by ischemia-reperfusion in vivo and hypoxia-reoxygenation in vitro.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: